This forum is an un-mediated, patient-to-patient forum for questions and support regarding Hepatitis B. Topics in this forum include but are not limited to, Causes, Diagnosis, Family and Relationships, Living With Hepatitis B, Research Updates, Treatment, Success Stories, Support, Symptoms.
Acc to conference materials: Result of hbsag 10 iu/ml leads to hbsag clearance only in 2% !!! Why in the world people conducting the trial did not extend theraphy and go beyond 48 weeks to cure these people? Why is it always about 48 weeks even if such promising low titer is achieved?
Acc to conference materials: Result of hbsag 10 iu/ml leads to hbsag clearance only in 2% if INF also stopped !!! Why in the world people conducting the trial did not extend theraphy and go beyond 48 weeks to cure these people? Why is it always about 48 weeks even if such promising low titer is achieved?
in italy they do extend in normal clinical practice, it is the doctor's choice.
they should change guidelines since it is clear that pegintf stop depends only on hbsag response or sides effects but it is also clear that they are afraid of costs.....we will see such big changes when all these stupid patents go where they belong, the trash
Thanks for the links. More time devoted to HCV, don't blame them, maybe next year conference will be just on HBV.
The HBV part of the conference seems to be subdued, no new treatment protocol for a cure, and no new drug development. I am disappointed to read that IFN lambda seems to be inferior to IFN alpha for HBeAg+ patients. Did I read that wrong? I always assume lambda was slightly better?!
i am unable to find the 2012 AASLD ifn lambda HBV eAg pos presentation, that Jake Liang is referring to. This could mean that BMS will halt the entire development of ifn lambda, since the HCV market for interferon is likely to shrink dramatically in the near future.
it would be important to see the actual data on this. Jake placed the message in RED , that should mean it was pretty inferior.
I hope you had the chance to watch the video of the presentation by Jake Liang. I think the results of the trial of HBeAg+ patients comparing IFN alpha and lambda have not been published (that is why you cannot find it). But he said the result that alpha is inferior is well known through the grape vine. And he offered a very good explanation too.
He is not very excited by therapeutic vaccines, but is encouraged by the result of GS9620.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.